Cholesterol-reduction intervention study (CRIS): A randomized trial to assess effectiveness and costs in clinical practice

Archives of Internal Medicine

Volumn 156, Issue 7, 1996, Pages 731-739

  Oster, Gerry ^a   Borok, Gerald M ^b   Menzin, Joseph ^a   Heyse, Joseph F ^c   Epstein, Robert S ^c   Quinn, Virginia ^b   Benson, Victor ^b   Dudl, R James ^b   Epstein, Arnold M ^d,e  

^a POLICY ANALYSIS INC PAI   (United States)

^b KAISER PERMANENTE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEVINOLIN;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MALE; MIDDLE AGED; NIACIN; TREATMENT OUTCOME;

EID: 0029872473     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.7.731     Document Type: Article

References (36)

1. Lipids Research Clinics Program The Lipids Research Clinics Coronary Primary Prevention Trial results, I. reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.
2. Expert Panel Report of the National Cholesterol Education Program expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988,148 36-69
3. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefits with niacin J Am Coll Cardiol. 1986, 8:1245-1255
4. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231 360-381.
5. Henkin Y, Oberman A, Hurst D, Segrest JP. Niacin revisited: clinical observations on an important but underutilized drug Am J Med. 1991;91:239-246.
6. Schectman G, Hiatt J, Hartz A Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans Am J Cardiol 1993,71:759-765
7. Lederle FA, Rogers EM Lowering the cost of lowering the cholesterol, formulary policy for lovastatin J Gen Intern Med 1990:5 459-463
8. Ray WA, Griffin MR, Avorn J. Evaluating drugs after their approval for clinical use. N Engl J Med 1993;329:2029-2032.
9. Oster G, Borok G, Menzin J, et al. A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol-Reduction Intervention Study (CRIS) Control Clin Trials. 1995,16:3-16.
10. The Lovastatin Study Group II. Therapeutic response to lovastatin (Mevinolin) in nonfamilial hypercholesterolemia, a multicenter study JAMA. 1986;256: 2829-2834
11. Tikkanen MJ, Helve E, Jaattela A, et al Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study. Am J Cardiol 1988,62:35J-43J
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem. 1972,18 499-502
13. Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey. reliability and validity in a patient population. Med Care. 1988;26:724-735.
14. Davies AR, Ware JE. GHAA's Consumer Satisfaction Survey and User's Manual. Newton, Mass: Group Health Association of America/Davies & Ware; 1988.
15. Three-Day Cholesterol Control Reporter. South Pasadena, Calif. Nutrition Scientific Inc, 1989.
16. 1993 Drug Topics Red Book. Montvale, NJ: Medical Economics Co Inc, 1992.
17. Schafermeyer KW, Schondelmeyer SW, Thomas J, Proctor K An analysis of the cost of dispensing third-party prescriptions in chain pharmacies. J Res Pharm Econ. 1992;4(3):3-24.
18. Health Care Financing Administration. Addendum B: relative value units and related information. Federal Register 1991;56:59631-59784
19. College of American Pathologists, Workload Recording Committee Manual for Laboratory Workload Recording Method. 1983 ed Skokie, III: College of American Pathologists; 1983.
20. Current Ratas Report: 01/25/93. Baltimore, Md: Maryland Health Services Cost Review Commission, 1993.
21. Mantel N. Chi-square tests with one degree of freedom, extensions of the Mantel-Haenszel procedure J Am Stat Assoc 1963;58.690-700.
22. Fleiss JL. The Design and Analysis of Clinical Experiments New York, NY John Wiley & Sons Inc, 1986.
23. Gail M, Simon R. Testing for qualitative interactions between treatment effects in patient subsets Biometrics. 1985;41 361-372
24. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985;34:642-65Q.
25. Luria MH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch Intern Med. 1988;148:2493-2495.
26. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Second report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1333-1445.
27. Grundy SM, Goodman DS, Rifkind BM, Cleeman JI. The place of HDL in cholesterol management: a perspective from the National Cholesterol Education Program. Arch Intern Med. 1989;149:505-510
28. Oster G, Epstein AM. Cost-effectiveness of antihypertipidemic therapy in the prevention of coronary heart disease: the case of cholestyramine. JAMA 1987, 258:2381-2387.
29. Kinosian BP, Eisenberg JM. Cutting into cholesterol: cost-effective alternatives for treating hypercholesterolemia. JAMA. 1988;269:2249-2254.
30. Schwartz D, Lellouch J Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis. 1967,20 637-648
31. Sackett DL The competing objectives of randomized trials. N Engl J Med 1980 303 1059-1060.
32. Brensike JF, Levy RI, Kelsi SF. Effects of therapy with cholestyramine on progression of arteriosclerosis: results of the NHLBI type II coronary intervention study. Circulation. 1984;69:313-324.
33. Keenan JM, Fontaine PL, Wenz JB, Myers S, Huang Z, Ripson CM. Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med 1991;151:1424-1432.
34. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovaslatin (EXCEL) study results, I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991,151:43-49.
35. Multiple Risk Factor Intervention Trial Research Group. The Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982; 248:1465-1477.
36. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program, I. reduction in mortality of persons with high blood pressure, Including mild hypertension. JAMA. 1979,242:2562-2571.